The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies

Journal of Clinical Investigation

Volumn 121, Issue 11, 2011, Pages 4537-4547

  Li, Conglei ^a,b   Piran, Siavash ^a,b   Chen, Pingguo ^b,c   Lang, Sean ^a,b,c   Zarpellon, Alessandro ^d   Jin, Joseph W ^b,c   Zhu, Guangheng ^b   Reheman, Adili ^b   Van Der Wal, Dianne E ^b   Simpson, Elisa K ^a,b   Ni, Ran ^e   Gross, Peter L ^e   Ware, Jerry ^f   Ruggeri, Zaverio M ^d   Freedman, John ^a,b,g   Ni, Heyu ^a,b,c,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; FC RECEPTOR; GLYCOPROTEIN IB ALPHA; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FETAL AND NEONATAL IMMUNE THROMBOCYTOPENIA; FIBRIN DEPOSITION; FIBRIN FORMATION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PLACENTA; PLACENTA FUNCTION; PREGNANCY; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOGENESIS;

ABORTION, SPONTANEOUS; ANIMALS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY, MATERNAL-FETAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTEGRIN BETA3; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PREGNANCY; RECEPTORS, FC; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 80555134759     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI57850     Document Type: Article

References (77)

1. Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev. 2008;22(1):33-52. (Pubitemid 351193026)
2. Kaplan C. Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis. 2006;1:39.
3. Blanchette VS, Chen L, de Friedberg ZS, Hogan VA, Trudel E, Decary F. Alloimmunization to the PlA1 platelet antigen: results of a prospective study. Br J Haematol. 1990;74(2):209-215. (Pubitemid 20041097)
4. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand- Zaleski I, Tchernia G. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood. 1997;89(12):4402-4406. (Pubitemid 27260250)
5. Herman JH, Jumbelic MI, Ancona RJ, Kickler TS. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am J Pediatr Hematol Oncol. 1986; 8(4):312-317. (Pubitemid 17229764)
6. Weiner E, et al. Direct fetal administration of immunoglobulins: another disappointing therapy in alloimmune thrombocytopenia. Fetal Diagn Ther. 1994;9(3):159-164. (Pubitemid 24179034)
7. Gaddipati S, Berkowitz RL, Lembet AA, Lapinski R, McFarland JG, Bussel JB. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol. 2001; 185(4):976-980. (Pubitemid 32980548)
8. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997;337(1):22-26. (Pubitemid 27290843)
9. Bertrand G, Drame M, Martageix C, Kaplan C. Prediction of the fetal status in non-invasive management of alloimmune thrombocytopenia. Blood. 2011;117(11):3209-3213.
10. Mueller-Eckhardt C, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1(8634):363-366. (Pubitemid 19103082)
11. Murphy MF, Hambley H, Nicolaides K, Waters AH. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn. 1996;16(12):1152-1155. (Pubitemid 27007638)
12. Ghevaert C, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion. 2007;47(5):901-910. (Pubitemid 46669006)
13. Kjeldsen-Kragh J, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007; 110(3):833-839. (Pubitemid 47267418)
14. Brass LF, Zhu L, Stalker TJ. Minding the gaps to promote thrombus growth and stability. J Clin Invest. 2005;115(12):3385-3392. (Pubitemid 43121823)
15. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007;109(12):5087-5095. (Pubitemid 46890522)
16. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost. 1997;78(1):611-616. (Pubitemid 27289313)
17. Schoenwaelder SM, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114(3):663-666.
18. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22(9):1381-1389.
19. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost. 2002;88(2):186-193. (Pubitemid 34873696)
20. Williamson LM, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92(7):2280-2287. (Pubitemid 28452968)
21. Kroll H, Kiefel V, Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sang. 1998; 74(suppl 2):345-354. (Pubitemid 28379804)
22. Bizzaro N, Dianese G. Neonatal alloimmune amegakaryocytosis. Case report. Vox Sang. 1988; 54(2):112-114.
23. Goldman M, Trudel E, Richard L, Khalife S, Spurll GM. Neonatal alloimmune thrombocytopenia due to anti-HPA-2b (anti-Koa). Immunohematology. 2003;19(2):43-46. (Pubitemid 36666012)
24. Kroll H, Kiefel V, Muntean W, Mueller-Eckhardt C. Anti-KOa as the cause of neonatal alloimmune thrombocytopenia. Vox Sang. 1994;67(suppl):12.
25. Al-Sheikh IH, Khalifa M, Rahi A, Qadri MI, Al Abad K. A rare case of neonatal alloimmune thrombocytopenia due to ANTI-HPA-2b. Ann Saudi Med. 1998; 18(6):547-549. (Pubitemid 29112780)
26. Grenet P, Dausset J, Dugas M, Petit D, Badoual J, Tangun Y. [Neonatal thrombopenic purpura with anti-Ko-a feto-maternal isoimmunization]. Arch Fr Pediatr. 1965;22(10):1165-1174.
27. Davoren A, Curtis BR, Aster RH, McFarland JG. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion. 2004;44(8):1220-1225. (Pubitemid 38989755)
28. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008.
29. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163-1175.
30. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994;83(4):1024-1032. (Pubitemid 24058552)
31. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 2000;95(3):886-893. (Pubitemid 30062710)
32. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood. 2002; 100(6):2102-2107. (Pubitemid 35001244)
33. Bergmeier W, et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A. 2006;103(45):16900-16905. (Pubitemid 44737350)
34. Ni H, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood. 2006;107(7):2976-2983.
35. Chen P, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood. 2010; 116(18):3660-3668.
36. Sarig G, Vidergor G, Brenner B. Assessment and management of high-risk pregnancies in women with thrombophilia. Blood Rev. 2009;23(4):143-147.
37. Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song WC. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med. 2005;11(2):153-159. (Pubitemid 40321350)
38. Redecha P, van Rooijen N, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood. 2009;113(17):4101-4109.
39. Olsson A, Andersson PO, Tengborn L, Wadenvik H. Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function. Thromb Res. 2002;107(3-4):135-139. (Pubitemid 35341501)
40. Yanabu M, et al. Influences of antiplatelet autoantibodies on platelet function in immune thrombocytopenic purpura. Eur J Haematol. 1991; 46(2):101-106.
41. Matsubayashi H, Weidner J, Miraglia CC, McIntyre JA. Platelet membrane early activation markers during prolonged storage. Thromb Res. 1999;93(4):151-160. (Pubitemid 29098961)
42. Zarpellon A, et al. Binding of alpha-thrombin to surface-anchored platelet glycoprotein Ib(alpha) sulfotyrosines through a two-site mechanism involving exosite I. Proc Natl Acad Sci U S A. 2011; 108(21):8628-8633.
43. Zampolli A, Roberts JR, Marchese P, Ruggeri ZM. Functional thrombin modulation in vivo by platelet glycoprotein Ib. J Thromb Haemost. 2009; 7(suppl 2):181.
44. Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood. 2003; 102(10):3609-3614. (Pubitemid 37409378)
45. Reheman A, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood. 2009;113(8):1809-1817.
46. Ni H, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000; 106(3):385-392. (Pubitemid 30655638)
47. Nicolini U, et al. Continuing controversy in alloimmune thrombocytopenia: fetal hyperimmunoglobulinemia fails to prevent thrombocytopenia. Am J Obstet Gynecol. 1990;163(4 pt 1):1144-1146. (Pubitemid 20377385)
48. Webster ML, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006;108(3):943-946. (Pubitemid 44154629)
49. Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica. 2007;92(2):283-284. (Pubitemid 46852445)
50. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol. 2000;18:739-766. (Pubitemid 30365396)
51. Roopenian DC, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170(7):3528-3533. (Pubitemid 36359219)
52. Firan M, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol. 2001;13(8):993-1002. (Pubitemid 32750502)
53. Lens D, et al. Association between recurrent pregnancy loss and prothrombotic gene polymorphisms. J Thromb Haemost. 2003;1(suppl 1):P0951.
54. Hickstein H, Barz D, Kulz T, Korten G, Muller H, Schmidt R. Protein A immunoadsorption in a pregnant woman with habitual abortion. Transfus Apher Sci. 2002;27(3):259-261. (Pubitemid 35341663)
55. Peng TC, Kickler TS, Bell WR, Haller E. Obstetric complications in a patient with Bernard-Soulier syndrome. Am J Obstet Gynecol. 1991;165(2):425-426.
56. Fujimori K, Ohto H, Honda S, Sato A. Antepartum diagnosis of fetal intracranial hemorrhage due to maternal Bernard-Soulier syndrome. Obstet Gynecol. 1999;94(5 pt 2):817-819. (Pubitemid 29490892)
57. Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham EG, Kadir RA. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia. 2010; 16(4):584-591.
58. Woodrow JC, Finn R. Transplacental haemorrhage. Br J Haematol. 1966;12(3):297-309.
59. Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986;51(2):117-121. (Pubitemid 16046151)
60. Kumpel BM, Sibley K, Jackson DJ, White G, Soothill PW. Ultrastructural localization of glycoprotein IIIa (GPIIIa, beta 3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion. 2008; 48(10):2077-2086.
61. Kumpel B, et al. Phenotype and mRNA expression of syncytiotrophoblast microparticles isolated from human placenta. Ann N Y Acad Sci. 2008; 1137:144-147.
62. Konkle BA, Shapiro SS, Asch AS, Nachman RL. Cytokine-enhanced expression of glycoprotein Ib alpha in human endothelium. J Biol Chem. 1990; 265(32):19833-19838. (Pubitemid 120013938)
63. Rajagopalan V, Essex DW, Shapiro SS, Konkle BA. Tumor necrosis factor-alpha modulation of glycoprotein Ib alpha expression in human endothelial and erythroleukemia cells. Blood. 1992; 80(1):153-161.
64. Wu G, et al. Human endothelial cells in culture and in vivo express on their surface all four components of the glycoprotein Ib/IX/V complex. Blood. 1997;90(7):2660-2669. (Pubitemid 27413476)
65. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ. 1997;315(7099):32-34. (Pubitemid 27271683)
66. Wilcox AJ, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319(4):189-194.
67. Schallmoser K, et al. The Fc gammaRIIa polymorphism R/H131, autoantibodies against the platelet receptors GPIb alpha and Fc gammaRIIa and a risk for thromboembolism in lupus anticoagulant patients. Thromb Haemost. 2005;93(3):544-548. (Pubitemid 40392544)
68. Isermann B, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003;9(3):331-337. (Pubitemid 36362789)
69. Vanhoorelbeke K, Ulrichts H, Van de Walle G, Fontayne A, Deckmyn H. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des. 2007;13(26):2684-2697. (Pubitemid 47430434)
70. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004; 76(3):205-213. (Pubitemid 38828837)
71. Sarpatwari A, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010;95(7):1167-1175.
72. Thachil J, Callaghan T, Martlew V. Thromboembolic events are not uncommon in patients with immune thrombocytopenia. Br J Haematol. 2010;150(4):496-497.
73. Kanhai HH, et al. Management of alloimmune thrombocytopenia. Vox Sang. 2007;93(4):370-385. (Pubitemid 350135084)
74. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A. 2000;97(6):2803-2808. (Pubitemid 30159252)
75. Hodivala-Dilke KM, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238. (Pubitemid 29053141)
76. Chang M, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-895. (Pubitemid 36917780)
77. Cosemans JM, et al. Key role of glycoprotein Ib/ V/IX and von Willebrand factor in platelet activation- dependent fibrin formation at low shear flow. Blood. 2011;117(2):651-660.